All Outputs (23)

Anticancer profile of newly synthesized BRAF inhibitors possess 5-(pyrimidin-4-yl)imidazo[2,1-b]thiazole scaffold (2019)
Journal Article
Abdel-Maksoud, M. S., Ammar, U. M., & Oh, C.-H. (2019). Anticancer profile of newly synthesized BRAF inhibitors possess 5-(pyrimidin-4-yl)imidazo[2,1-b]thiazole scaffold. Bioorganic and Medicinal Chemistry, 27(10), 2041-2051. https://doi.org/10.1016/j.bmc.2019.03.062

In this work, a new series of imidazo[2,1-b]thiazole was designed and synthesized. The new compounds are having 3-fluorophenyl at position 6 of imidazo[2,1-b]thiazole and pyrimidine ring at position 5. The pyrimidine ring containing either amide or s... Read More about Anticancer profile of newly synthesized BRAF inhibitors possess 5-(pyrimidin-4-yl)imidazo[2,1-b]thiazole scaffold.

Recent advances of RAF (rapidly accelerated fibrosarcoma) inhibitors as anti-cancer agents (2018)
Journal Article
Ammar, U. M., Abdel-Maksoud, M. S., & Oh, C.-H. (2018). Recent advances of RAF (rapidly accelerated fibrosarcoma) inhibitors as anti-cancer agents. European Journal of Medicinal Chemistry, 158, 144-166. https://doi.org/10.1016/j.ejmech.2018.09.005

Frequent oncogenic mutations have been identified in MAPK (mitogen-activated protein kinase) signaling pathway components. As a result, MAPK pathway is associated with human cancer initiation, in particular RAF (rapidly accelerated fibrosarcoma) comp... Read More about Recent advances of RAF (rapidly accelerated fibrosarcoma) inhibitors as anti-cancer agents.

Design, synthesis, anticancer evaluation and molecular docking of new V600EBRAF inhibitors derived from pyridopyrazinone (2016)
Journal Article
Amin, K., El-Badry, O., Abdel Rahman, D., Ammar, U., & Abdalla, M. (2016). Design, synthesis, anticancer evaluation and molecular docking of new V600EBRAF inhibitors derived from pyridopyrazinone. European Journal of Chemistry, 7(1), 19-29. https://doi.org/10.5155/eurjchem.7.1.19-29.1346

Design and synthesis of some new pyridopyrazinone derivatives as anti-proliferative agents is described. The cytotoxic activities of the synthesized compounds against melanoma cell line (LOXIMVI), ovarian cell line (OVCAR3), thyroid cell lines (CAL62... Read More about Design, synthesis, anticancer evaluation and molecular docking of new V600EBRAF inhibitors derived from pyridopyrazinone.